Zobrazeno 41 - 50
of 77
pro vyhledávání: '"Aafke H. Honkoop"'
Autor:
Petronella B. Ottevanger, Peep F. M. Stalmeier, Aafke H. Honkoop, Winette T. A. van der Graaf, Agnes J. van de Wouw, Linda J. M. Oostendorp, Maartje Los
Publikováno v:
Journal of Cancer Education, 31, 3, pp. 443-8
Journal of Cancer Education, 31, 443-8
Journal of Cancer Education
Journal of Cancer Education, 31, 443-8
Journal of Cancer Education
Communication about palliative treatment options requires a balance between providing patients with sufficient information and not providing unwanted information. Surveys have indicated that many patients with advanced cancer express a wish to receiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa9c326deb5bb313f05ce33e7183721
https://hdl.handle.net/2066/171142
https://hdl.handle.net/2066/171142
Autor:
Carolien H. Smorenburg, Annette W.G. van der Velden, Elisabeth G.E. de Vries, Aafke H. Honkoop, Annelies H. Boekhout, Ido P. Kema, Bojana Milojkovic Kerklaan, Agnes J. van der Wouw, Jan H.M. Schellens, Erik van Werkhoven, Peter Nieboer, Caroline M.P.W. Mandigers, Maartje Los, Petronella B. Ottevanger, Lonneke Kessels, Dirk J. van Veldhuisen, Renske Altena, Tineke J. Smilde, Willem M. Smit, Jourik A. Gietema, Jaap de Boer
Publikováno v:
Jama Oncology, 2, 1030-7
Jama Oncology, 2, 8, pp. 1030-7
JAMA oncology, 2(8), 1030-1037. AMER MEDICAL ASSOC
Jama Oncology, 2, 8, pp. 1030-7
JAMA oncology, 2(8), 1030-1037. AMER MEDICAL ASSOC
Item does not contain fulltext IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2711005b972b1ee32911914e7a69418
http://hdl.handle.net/2066/171393
http://hdl.handle.net/2066/171393
Autor:
Aafke H. Honkoop, Bart Rikhof, Henk J. G. Bilo, Maarten A Alleman, Jan Willem B. de Groot, Jaap van Doorn, Winette T. A. van der Graaf
Publikováno v:
Endocrine-Related Cancer, 14, 979-93
Endocrine-Related Cancer, 14, 4, pp. 979-93
Endocrine-Related Cancer, 14, 4, pp. 979-93
Item does not contain fulltext This review focuses on the tumour types and symptoms associated with non-islet cell tumour-induced hypoglycaemia (NICTH) as well as the pathogenesis, diagnosis and treatment of this rare paraneoplastic phenomenon. In ad
Autor:
C.J. Rodenburg, Frans L. G. Erdkamp, J. Douma, Miriam Koopman, Aafke H. Honkoop, Gerard Vreugdenhil, J.M. Akkermans-Vogelaar, J. Wals, Ninja Antonini, C.J.A. Punt, R.S. de Jong
Publikováno v:
Annals of Oncology, 17, 10, pp. 1523-8
Annals of oncology, 17(10), 1523-1528. Oxford University Press
Annals of Oncology, 17, 1523-8
Annals of oncology, 17(10), 1523-1528. Oxford University Press
Annals of Oncology, 17, 1523-8
Contains fulltext : 50348.pdf (Publisher’s version ) (Closed access) BACKGROUND: Results on overall survival in randomised studies of mono- versus combination chemotherapy in advanced colorectal cancer patients may have been biased by an imbalance
Autor:
Judith R. Kroep, Alexander L T Imholz, Astrid C P Swinkels, Hiltje de Graaf, Carolien H. Smorenburg, Aafke H. Honkoop, Irene E. G. van Hellemond, Maaike de Boer, Ingeborg J. H. Vriens, Maurice J.C. van der Sangen, Wilfred K. de Roos, Vivianne C. G. Tjan-Heijnen, Caroline Seynaeve, Petronella G. M. Peer, Sabine C. Linn, Frans L. G. Erdkamp, Franchette W P J van den Berkmortel
Publikováno v:
Journal of Clinical Oncology. 35:523-523
523 Background: The DATA study compared 6 and 3 years of anastrozole therapy in postmenopausal women with hormone-receptor positive early breast cancer previously treated with 2-3 years tamoxifen (oral presentation SABCS 2016 #S01-03). The study incl
Autor:
Lidwine W. Tick, Gabe S. Sonke, Jelle Wesseling, Sabine C. Linn, Aafke H. Honkoop, Irma M. Oving, I.A.M. Mandjes, Inge Kemper, Caroline M.P.W. Mandigers, Erik van Werkhoven, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Mette S. van Ramshorst, Agnes W Van de Wouw
Publikováno v:
Journal of Clinical Oncology. 35:507-507
507 Background: Neoadjuvant chemotherapy with dual HER2 blockade boosts pathologic complete response (pCR) rates in HER2+ breast cancer. The optimal chemotherapy backbone in this setting is unknown. We conducted a multicenter phase III trial to study
Autor:
H.M. Oosterkamp, A.M.E. Walenkamp, M. Hanse, Aafke H. Honkoop, J. Buter, René M. Vernhout, Walter Taal, M. J. van den Bent, Pim J. French, P. A. E. Sillevis Smitt, L. Beerepoot, Johan M. Kros, Lale Erdem-Eraslan, B. van der Holt
INTRODUCTION: To assess the effects of bevacizumab (BEV) in recurrent GBMs, a three-arm randomized phase II study was initiated (the BELOB trial) comparing BEV monotherapy, CCNU monotherapy and BEV + CCNU combinationtherapy. Primary endpoint was 9 mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed37b0771c96cb34fd77bd69f49586b1
https://europepmc.org/articles/PMC4144494/
https://europepmc.org/articles/PMC4144494/
Autor:
J. van den Bosch, S. de Groot, Judith R. Kroep, Jürgen Braun, Siu W. Lam, Epie Boven, Sabine C. Linn, Monique M.E.M. Bos, H. van Tinteren, Aafke H. Honkoop, Agnes Jager, A. J. Ten Tije
Publikováno v:
European Journal of Cancer, 50(18), 3077-3088. Pergamon
Lam, S W, de Groot, S M, Honkoop, A H, Jager, A, ten Tije, A J, Bos, M M E M, Linn, S C, Bosch, J, Kroep, J R, Braun, J J, van Tinteren, H & Boven, E 2014, ' Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial ', European Journal of Cancer, vol. 50, no. 18, pp. 3077-3088 . https://doi.org/10.1016/j.ejca.2014.10.008
European Journal of Cancer, 50(18), 3077-3088
European Journal of Cancer, 50(18), 3077-3088. Elsevier Ltd.
Lam, S W, de Groot, S M, Honkoop, A H, Jager, A, ten Tije, A J, Bos, M M E M, Linn, S C, Bosch, J, Kroep, J R, Braun, J J, van Tinteren, H & Boven, E 2014, ' Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial ', European Journal of Cancer, vol. 50, no. 18, pp. 3077-3088 . https://doi.org/10.1016/j.ejca.2014.10.008
European Journal of Cancer, 50(18), 3077-3088
European Journal of Cancer, 50(18), 3077-3088. Elsevier Ltd.
Background: The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival (PFS) and objective response rate (ORR) as compared with chemotherapy alone in patients with HER2-negative locally recurrent or
Autor:
H. Bonnefoi, H.W.M. van Laarhoven, H.C. van den Hout, Carolien H. Smorenburg, Aafke H. Honkoop, Etienne Brain, Gabe S. Sonke, A. Goldhirsch, C.A. Drukker, Nadia Harbeck, Marjanka K. Schmidt, Rutger H. T. Koornstra, Johanneke E.A. Portielje, Fatima Cardoso, Sabine C. Linn, Andreas Schneeweiss, Jacqueline M. Stouthard
Publikováno v:
European Journal of Cancer, 50, 6, pp. 1045-54
European Journal of Cancer, 50, 1045-54
European journal of cancer (Oxford, England, 50(6), 1045-1054. Elsevier Limited
European Journal of Cancer, 50, 1045-54
European journal of cancer (Oxford, England, 50(6), 1045-1054. Elsevier Limited
Contains fulltext : 136740.pdf (Publisher’s version ) (Open Access) BACKGROUND: Clinical decision-making in patients with early stage breast cancer requires adequate risk estimation by medical oncologists. This survey evaluates the agreement among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f5e1877556283fb000c3173fac7359f
https://hdl.handle.net/2066/136740
https://hdl.handle.net/2066/136740
Autor:
Linda Mol, Cornelis J. A. Punt, Ninja Antonini, Otilia Dalesio, Aafke H. Honkoop, Marjon J. B. P. Werter, Miriam Koopman, Robert S. de Jong, Jaap Wals, Aart van Bochove, Gerard Vreugdenhil, Peter H. Th J. Slee, Geert-Jan Creemers, Frans L. G. Erdkamp, C.J. Rodenburg, Margot E T Tesselaar, Olaf J. L. Loosveld, Joep Douma, Harm Sinnige
Publikováno v:
Lancet, 370(9582), 135-142. Elsevier Limited
The Lancet (London), 370, 9582, pp. 135-42
The Lancet (London), 370, 135-42
The Lancet (London), 370, 9582, pp. 135-42
The Lancet (London), 370, 135-42
Contains fulltext : 52831.pdf (Publisher’s version ) (Closed access) BACKGROUND: The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination treatment is better than sequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b25612a88d11f941ba4a69b8edd93e76
https://doi.org/10.1016/S0140-6736(07)61086-1
https://doi.org/10.1016/S0140-6736(07)61086-1